Drug Trial Radar · NCT01131676
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Last checked: Nov 19, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,064
Actual
Start
Jul 2010
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- May 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
Conditions
- Diabetes Mellitus, Type 2
Interventions
BI 10773 low doseDrug
BI 10773 tablets once daily
Placebo BI 10773 high doseDrug
Placebo tablets identical to BI 10773
BI 10773 high doseDrug
BI 10773 tablets once daily
Placebo BI 10773 low doseDrug
Placebo tablets identical to BI 10773
Placebo BI 10773 low doseDrug
Placebo tablets identical to BI 10773
Placebo BI 10773 high doseDrug
Placebo tablets identical to BI 10773
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.Time frame: From randomisation to individual end of observation, up to 4.6 years
Locations
615 sites in 42 countries. Site status is shown where the registry gives one.
1245.25.10043 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1245.25.10121 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1245.25.10037 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
1245.25.10124 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1245.25.10015 Boehringer Ingelheim Investigational Site
Little Rock, Alaska
1245.25.10056 Boehringer Ingelheim Investigational Site
Gilbert, Arizona
1245.25.10175 Boehringer Ingelheim Investigational Site
Peoria, Arizona
1245.25.10072 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1245.25.10048 Boehringer Ingelheim Investigational Site
Harrisburg, Arkansas
1245.25.10035 Boehringer Ingelheim Investigational Site
Anaheim, California
1245.25.10103 Boehringer Ingelheim Investigational Site
Encino, California
1245.25.10158 Boehringer Ingelheim Investigational Site
Fresno, California
1245.25.10126 Boehringer Ingelheim Investigational Site
Harbor City, California
1245.25.10058 Boehringer Ingelheim Investigational Site
Huntington Park, California
1245.25.10001 Boehringer Ingelheim Investigational Site
Lancaster, California
1245.25.10102 Boehringer Ingelheim Investigational Site
Los Angeles, California
1245.25.10047 Boehringer Ingelheim Investigational Site
Los Gatos, California
1245.25.10118 Boehringer Ingelheim Investigational Site
Palm Springs, California
1245.25.10061 Boehringer Ingelheim Investigational Site
Riverside, California
1245.25.10040 Boehringer Ingelheim Investigational Site
San Diego, California
1245.25.10055 Boehringer Ingelheim Investigational Site
San Diego, California
1245.25.10193 Boehringer Ingelheim Investigational Site
San Diego, California
1245.25.10027 Boehringer Ingelheim Investigational Site
Santa Rosa, California
1245.25.10074 Boehringer Ingelheim Investigational Site
Stockton, California
1245.25.10083 Boehringer Ingelheim Investigational Site
Valencia, California
1245.25.10144 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1245.25.10085 Boehringer Ingelheim Investigational Site
Denver, Colorado
1245.25.10153 Boehringer Ingelheim Investigational Site
Denver, Colorado
1245.25.10066 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
1245.25.10038 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
1245.25.10068 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
1245.25.10094 Boehringer Ingelheim Investigational Site
Bradenton, Florida
1245.25.10190 Boehringer Ingelheim Investigational Site
Brooksville, Florida
1245.25.10209 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1245.25.10212 Boehringer Ingelheim Investigational Site
Cooper City, Florida
1245.25.10200 Boehringer Ingelheim Investigational Site
Delray Beach, Florida
1245.25.10033 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida
1245.25.10202 Boehringer Ingelheim Investigational Site
Hallandale, Florida
1245.25.10062 Boehringer Ingelheim Investigational Site
Hialeah, Florida
1245.25.10063 Boehringer Ingelheim Investigational Site
Hialeah, Florida
Showing 40 of 615 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.